Juno Therapeutics (JUNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2016 | 06-2016 | 03-2016 | 12-2015 | 09-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 223,420 | 285,343 | 316,007 | 252,398 | 569,137 |
| Marketable Securities | 597,236 | 671,564 | 630,963 | 691,013 | 598,634 |
| Receivables | 10,603 | 9,311 | N/A | 315 | N/A |
| TOTAL | $844,773 | $974,578 | $955,956 | $951,839 | $1,172,972 |
| Non-Current Assets | |||||
| PPE Net | 57,708 | 51,480 | 44,970 | 42,086 | 36,874 |
| Investments And Advances | 214,880 | 153,086 | 178,290 | 272,888 | 99,952 |
| Intangibles | 301,441 | 301,112 | 301,888 | 172,269 | 173,311 |
| Other Non-Current Assets | 7,495 | 8,348 | 8,815 | 6,046 | 5,553 |
| TOTAL | $581,524 | $514,026 | $533,963 | $493,289 | $315,690 |
| Total Assets | $1,426,297 | $1,488,604 | $1,489,919 | $1,445,128 | $1,488,662 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,740 | 3,191 | 2,168 | 4,248 | 2,964 |
| Accrued Expenses | 44,115 | 42,289 | 31,243 | 33,376 | 28,904 |
| Other current liabilities | 43,773 | 56,817 | 57,915 | 66,734 | 102,204 |
| TOTAL | $133,031 | $143,689 | $106,675 | $119,728 | $149,432 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 41,403 | 41,392 | 15,349 | 15,370 | 15,360 |
| Other Non-Current Liabilities | 30,251 | 28,911 | 27,589 | 35,796 | 38,840 |
| TOTAL | $176,329 | $186,235 | $171,360 | $183,867 | $192,316 |
| Total Liabilities | $309,360 | $329,924 | $278,035 | $303,595 | $341,748 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 105,871 | 105,779 | 105,536 | 104,060 | 100,617 |
| Common Shares | 10 | 10 | 10 | 10 | 10 |
| Retained earnings | -778,459 | -721,562 | -656,795 | -585,657 | -500,444 |
| Other shareholders' equity | -439 | -463 | -4,900 | -6,083 | -1,398 |
| TOTAL | $1,116,937 | $1,158,680 | $1,211,884 | $1,141,533 | $1,146,914 |
| Total Liabilities And Equity | $1,426,297 | $1,488,604 | $1,489,919 | $1,445,128 | $1,488,662 |